ARTICLE | Company News
Novartis exercises option for Conatus NASH candidate emricasan
May 5, 2017 1:37 AM UTC
Novartis AG (NYSE:NVS; SIX:NOVN) exercised an option for exclusive, worldwide rights to emricasan from Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) under a December 2016 deal. Conatus will receive a $7 million option exercise payment (see BioCentury, Dec. 28, 2016)...
BCIQ Target Profiles